Cangrelor is a P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST). Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors.
- Mechanism
- Curator reviewed
Cangrelor is a selective, reversible, P2Y12 platelet receptor antagonist which inhibits ADP platelet aggregation. ADP is typically released by damaged blood vessels, red blood cells, and/or platelets due to agonists stimulating platelet activity. ADP binds to P2Y12 to stimulate and complete platelet aggregation by inhibiting adenylyl cyclase by a Gi protein, thus potentiating dense granule secretion and increasing coagulation activity. Cangrelor acts on the same target as oral irreversible inhibitors clopidogrel and ticlopidine and has a similar mechanism of action, but is reversible and provides a fast onset and offset of action.
- Primary indication
- For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with...Curator reviewed · 3 structured indications
- Formula / weight
- C17H25Cl2F3N5O12P3S2 · 776.35 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2015 · European Union, 2016
- Code names
- AR69931 · AR-C69931XX
- Brand names
Resolves to
PAEBIVWUMLRPSK-IDTAVKCVSA-NSMILESCSCCNC1=C2N=CN([C@@H]3O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC(SCCC(F)(F)F)=N1What you can answer from here — as of September 12, 2026
Which drugs share a target with Cangrelor, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account